Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clofarabine, Idarubicin, and Cytarabine Combination as Induction Therapy for Younger Patients With Acute Myeloid Leukemia (AML).

Next Previous
Trial Profile

Clofarabine, Idarubicin, and Cytarabine Combination as Induction Therapy for Younger Patients With Acute Myeloid Leukemia (AML).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clofarabine (Primary) ; Cytarabine (Primary) ; Idarubicin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use

Most Recent Events

  • 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 01 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
  • 09 Mar 2011 New source identified and integrated (M.D. Anderson Cancer Center).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top